Results 121 to 130 of about 28,421 (276)
Advanced Science, Volume 12, Issue 39, October 20, 2025.Targeting Kupffer cells (KC) with a single intravenous infusion of the oncolytic virus VSV‐M51R rather than VSV‐WT induces effective tumor regression in various types of liver metastatic cancers in mice. VSV‐M51R promotes KC proliferation and enhances their antigen cross‐presentation capacity without compromising viability, leading to the induction of ...
Chen Chen +8 more
wiley +1 more source
The impact of hypoxia on oncolytic virotherapy [PDF]
, 2011 The hypoxic tumor microenvironment plays significant roles in tumor cell metabolism and survival, tumor growth, and progression. Hypoxia modulates target genes in target cells mainly through an oxygen-sensing signaling pathway mediated by hypoxia ...
Sheng Guo, Z
core +3 more sources
Advanced Science, Volume 12, Issue 40, October 27, 2025.A personalized nanovaccine combining PLGA‐encapsulated heat‐inactivated CVB3 and membranes from CVB3‐infected breast cancer cells stimulates potent antitumor immunity. It reduces immunosuppressive markers, enhances immune activation, and improves survival in vivo.
Amirhossein Bahreyni +6 more
wiley +1 more source
Literature review: Virus and cancer [PDF]
, 2017 Traballo fin de grao (UDC.CIE). Bioloxía. Curso 2016/2017[Abstract] Cancer is one of the main causes of global mortality, and even though it is considered to be a non-communicable disease, several infectious agents have been found to contribute to ...
Carreira Santos, Sofía
core
Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy [PDF]
, 2014 Despite initial promising results, the success of clinical trials testing oncolytic viruses in glioblastoma patients has been limited. Innate immunity appears to be one among several barriers against successful viral oncolysis.
Alvarez-Breckenridge, Christopher A. +3 more
core +1 more source
In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation
Advanced Science, Volume 12, Issue 37, October 6, 2025.In this review, the basic concepts of in situ vaccination are discussed, its advantages over conventional vaccines, and key historical milestones, from the first use of Coley's toxins to the most recent FDA‐approved in situ vaccine for bladder cancer.
Yiru Shi +4 more
wiley +1 more source
TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma
Molecular Therapy: Oncolytics, 2017 Oncolytic viruses are an emerging class of cancer therapeutics that couple cytotoxicity with the induction of an anti-tumor immune response. Host-virus interactions are complex and modulated by a tumor microenvironment whose immunosuppressive activities ...
Brian Hutzen +8 more
doaj +1 more source
Scientific Reports, 2023 Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Innovative treatment is required to improve overall survival rates for advanced NSCLC.
Akira Sakamoto +5 more
doaj +1 more source
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies [PDF]
, 2016 Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapies. Human adenovirus type 5 (HAdV-C5/Ad5) is a common vector for its ease of manipulation, high production titers and capacity to transduce multiple cell ...
Chester, John +4 more
core +1 more source
Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
OncoImmunology, 2019 Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or ...
Maria Eugenia Davola +1 more
doaj +1 more source